Tarsus Pharmaceuticals, Inc. (TARS) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Momentum 1.2/10 is below the 5.0 floor at $60.91 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Product: XDEMVY; Earnings in 6 days (event risk).
Tarsus Pharmaceuticals is a commercial-stage biopharmaceutical company focused on eye care. It launched XDEMVY (lotilaner ophthalmic solution 0.25%) in August 2023, the first FDA-approved treatment for Demodex blepharitis, targeting an estimated 25 million affected Americans.... Read more
Sell if holding. Momentum 1.2/10 is below the 5.0 floor at $60.91 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Product: XDEMVY; Earnings in 6 days (event risk). Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.7/10, moderate confidence.
Passes 5/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum and earnings proximity 6d<=7d. Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductXDEMVY10-K Item 1A: 'We have one product, XDEMVY®...a single product approved for commercial sale'
Material Events(8-K, last 90d)
- 2026-02-18Item 5.02LOWBoard expanded from 7 to 8 directors; David E.I. Pyott appointed as Class III director effective February 18, 2026. Appointed Chair of Commercial Committee and member of Nominating and Compensation Committees. No departure or disagreement cited.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers·1 ceiling hit
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Momentum 1.2/10 is below the 5.0 floor at $60.91 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Product: XDEMVY; Earnings in 6 days (event risk). Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $58.08. Score 5.7/10, moderate confidence.
Take-profit target: $81.97 (+34.6% upside). Prior stop was $58.08. Stop-loss: $58.08.
Concentration risk — Product: XDEMVY; Earnings in 6 days (event risk); Consecutive earnings misses (3).
Tarsus Pharmaceuticals, Inc. trades at a P/E of N/A (forward 20.6). TrendMatrix value score: 7.6/10. Verdict: Sell.
15 analysts cover TARS with a consensus score of 4.4/5. Average price target: $94.
What does Tarsus Pharmaceuticals, Inc. do?Tarsus Pharmaceuticals is a commercial-stage biopharmaceutical company focused on eye care. It launched XDEMVY...
Tarsus Pharmaceuticals is a commercial-stage biopharmaceutical company focused on eye care. It launched XDEMVY (lotilaner ophthalmic solution 0.25%) in August 2023, the first FDA-approved treatment for Demodex blepharitis, targeting an estimated 25 million affected Americans. Pipeline candidates include TP-04 for ocular rosacea and TP-05 for Lyme disease prophylaxis.